GlassScriptPhysician profile
Lawrence R Hess
NPI 1720176217
$3,272.35
in general payments reported to CMS, 2019-2025
28 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $997 · 2023: $615 · 2024: $800 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.12 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $496.86 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $431.54 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $401.49 | 2022-2025 | |
| Lilly USA, LLC | $233.64 | 2021-2025 | Zepbound, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $170.18 | 2021-2023 | Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $139.29 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $92.26 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $91.61 | 2021-2023 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $70.41 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.21 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.12 | 2022-2024 | Xifaxan |
| Nevro Corp. | $45.42 | 2022-2024 | Senza |
| Supernus Pharmaceuticals, INC. | $34.46 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $32.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.56 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $24.93 | 2022 | |
| Tolmar, INC. | $22.17 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $19.24 | 2022 | |
| Exact Sciences Corporation | $18.90 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $18.42 | 2025 | Freestyle Libre |
| Beta Bionics, INC. | $15.55 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.56 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $13.47 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.15 | 2022 | |
| Acerus Pharmaceuticals Corporation | $11.66 | 2021 | |
| Genentech USA, INC. | $7.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.